

Product Information

CellLytic™ B Cell Lysis Reagent

For bacterial cell lysis, standard strength

B7435

Product Description

CellLytic™ B is used for the lysis of bacterial cells for the purification of recombinant and wild type proteins. CellLytic™ B contains 40 mM Tris-HCl, pH 8.0, and a proprietary, non-denaturing formulation of zwitterionic detergents. There is no need for special equipment to disrupt cells such as a sonicator or French press. This fast one-step method obtains higher yields than sonication, lysozyme treatment, or other commercially available lysis solutions.

CellLytic™ B can be used to extract soluble proteins, and also to wash away cell debris from inclusion bodies to yield nearly pure protein. CellLytic™ B does not solubilize inclusion bodies.

CellLytic™ B is optimized for the lysis of *E. coli* strain BL21. However, it also works well for DH5α™, JM109, and other similar bacterial cells. Intact fusion proteins have been successfully purified from CellLytic™ B lysates of BL21 *E. coli* cells expressing His-tagged and FLAG®-tagged proteins, using HIS-Select™ and Anti-FLAG® M2 purification resins, respectively. The CellLytic™ B reagent is also compatible with affinity purification of other fusion proteins.

Several theses¹ and dissertations²⁻⁸ cite use of B7435 CellLytic™ B in their research protocols.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Reagent

CellLytic™ B is supplied as a ready-to-use solution.

Reagents and Equipment Required but Not Provided

(Cat. Nos. have been given where appropriate)

- Lysozyme Solution (Cat. No. L3790)
- Benzonase® (Cat. No. E1014)
- Deionized water, or molecular biology grade water (Cat. No. W4502), for dilution of CellLytic™ B
- HIS-Select™ Nickel Affinity Gel (Cat. No. P6611) or other fusion protein purification system
- Protease Inhibitor Cocktails for:
 - Bacterial cells, such as Cat. No. P8465
 - His-tagged proteins, such as Cat. Nos. P8849, S8830, PIC0004
- CellLytic™ IB (Cat. No. C5236)
- Appropriate centrifuge tubes
- Centrifuge

Storage/Stability

Store the product at room temperature. CellLytic™ B, as supplied, is stable for at least 2 years at room temperature.

Preparation Instructions

CellLytic™ B is a ready-to-use solution. Additional reagents may be added to suit particular needs. These include salts, protease inhibitors, EDTA (where appropriate; not recommended for purification of His-tagged proteins), or reducing agents such as dithiothreitol or 2-mercaptoethanol.

It is recommended that the entire Technical Bulletin be read prior to use, especially the Reagent Compatibility Chart.

Procedures

Trial-Scale Extraction

A small-scale trial extraction should be performed to determine the fraction in which the protein of interest will be found. If this has already been determined, proceed to the Large-Scale Extraction section.

1. A 5 mL culture of the bacterial strain that contains the recombinant protein should be grown under the appropriate conditions for expression.
2. Use 1.5 mL of the bacterial culture with an OD₆₀₀ of 0.5-1.0 and centrifuge the cells at full speed for minutes.
3. Remove the spent medium and resuspend the cell pellet in 0.4 mL of CelLytic™ B.
4. Briefly vortex the solution to resuspend the cell pellet. Mix for 5-10 minutes to ensure full extraction of the soluble proteins.
5. Centrifuge the cell lysate at full speed for 5 minutes to pellet any insoluble material.
6. Carefully remove the soluble protein fraction from the cell debris. Additional extractions may be performed if required. However, this will result in a more dilute soluble protein sample.
7. Analyze the supernatant and the insoluble fraction by SDS-PAGE and/or Western blot to determine which fraction contains the protein of interest. For SDS-PAGE, it is recommended that 5-15 µL of each sample be applied to the gel.

Note: If the protein of interest is not found in the soluble portion, it has likely formed inclusion bodies. For the purification/solubilization of inclusion bodies, see the Inclusion Body Purification Procedure, Section C.

Large-Scale Extraction

This procedure is designed for 1 gram of wet cell paste. This is roughly equivalent to a 250 mL bacterial culture with an OD₆₀₀ of ~2.0. To extract the maximum amount of soluble protein, the CelLytic™ B to cell mass ratio should be 10-20 mL per gram of wet cell paste. Using less CelLytic™ B will give a more concentrated solution, but a smaller amount of total protein will be extracted. Using more CelLytic™ B will not extract any more protein, and instead will only serve to provide a more dilute protein solution.

1. Collect the bacterial cells that express the protein of interest by centrifuging at 5,000 × *g* for 10 minutes.

2. Carefully remove the spent medium from the cell pellet. The cell pellet may be frozen or used fresh. A frozen cell pellet will give a slightly higher yield of protein.
3. Add CelLytic™ B at a ratio of 10-20 mL per gram of cell paste. Mix well to completely resuspend the cells. The following optional reagents may also be added:
 - Lysozyme (final concentration of 0.2 mg/mL) to enhance cell lysis.
 - Benzonase® (final amount of 50 units/mL) to decrease the viscosity of the solution.
 - Protease inhibitors to prevent proteolytic degradation.
4. Incubate the extraction suspension with shaking at room temperature for 10-15 minutes, to extract fully the soluble proteins from the cells.
5. After the cells have been extracted, centrifuge the extract at 16,000 × *g* for 10 minutes to pellet the insoluble material.
6. Carefully remove the supernatant containing the soluble protein fraction. Another round of extraction will yield more soluble protein if required. However, this will result in a more dilute soluble protein sample.
7. Analyze the supernatant and insoluble fraction by SDS-PAGE and/or Western blot to determine which fraction contains the protein of interest. For SDS-PAGE, it is recommended that 5-15 µL of each sample be applied to the gel.

Note: CelLytic™ B will **not** solubilize inclusion bodies. For purification of inclusion bodies, see the Inclusion Body Purification Procedure, Section C.

Inclusion Body Purification

1. Resuspend the cell pellet from the first extraction (Section A, Step 6; or Section B, Step 6) in a volume of CelLytic™ B solution equal to that used for the extraction. Vortex for 1-2 minutes to completely resuspend the cell debris. Add Lysozyme Solution (Cat. No. L3790) to a final concentration of 0.2 mg/mL.
2. Incubate at room temperature for 5-10 minutes to allow the lysozyme to fragment the cell wall.
3. Dilute CelLytic™ B 10-fold by mixing 90 mL of deionized water for every 10 mL of CelLytic™ B.
4. Add 30 mL of the 10-fold diluted CelLytic™ B per gram of paste from the original extraction to the tube. Mix thoroughly.



5. Centrifuge at full speed for 5 minutes to pellet the cell debris again. Save the supernatant for analysis.
6. Resuspend the pellet in a volume of 10-fold diluted CellLytic™ B equal to that was used in Step 4. Vortex to completely resuspend any remaining insoluble material.
7. Centrifuge at full speed for 5 minutes to pellet the inclusion bodies. Save the supernatant for analysis.

Note: Steps 5 and 6 may be repeated several times to remove completely any remaining soluble proteins and cell wall material from the inclusion bodies. This wash step should be optimized for the specific protein of interest.

8. Resuspend the washed inclusion bodies (pellet from Step 7) in an equal volume of deionized water or a buffer of choice.
9. Analyze all the saved supernatants and the insoluble fraction by SDS-PAGE and/or Western blot. For SDS-PAGE, it is recommended that 5-15 µL of each sample be applied to the gel.

Note: Alternatively, inclusion bodies can be solubilized in CellLytic™ IB (Cat. No. C5236).

References

1. Baumschlager, Armin, "Boosting of aromatic polyester degradation with enzymes derived from anaerobic *Clostridia*". Graz University of Technology, M.Sc. thesis, p. 94 (2013).
2. Walcher, Stephanie, "Optimizing Uniform Ligand Density on DNA Origami for Th1 Activation". IMC University of Applied Sciences (Krems, Austria), M.Sc. thesis, p. 32 (2017).
3. Simon-Deckers, Angélique, "Biological effects of manufactured nanoparticles: influence of their characteristics". Institut des Sciences et Industries du Vivant et de l'Environnement, Ph.D. dissertation, p. 230 (2008).
4. Zhou, Chun, "Effect of prostate cancer-related plexin-B1 mutations on cell signalling and function". University College London, Ph.D. dissertation, p. 169 (2009).
5. Werkman, Joshua Robert, "DNA-binding site recognition by bHLH and MADS-domain transcription factors". University of Kentucky, Ph.D. dissertation, pp. 43, 73 (2013).
6. Dhanapala, Pathum Ravinath, "Production and Characterization of Hypoallergenic Chicken Eggs". Deakin University, Ph.D. dissertation, p. 132 (2015).
7. Kamber Kaya, Hatem E., "Regulation of the *Drosophila* Initiator Caspase Dronc through Ubiquitylation". University of Massachusetts Medical School, Ph.D. dissertation, p. 113 (2017).
8. Wójcik, Magdalena, "Pathogenic, versatile and tunable activity of sortase, a transpeptidation machine". University of Groningen, Ph.D. dissertation, p. 143 (2020).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

MERCK

Troubleshooting Guide

Problem	Cause	Solution
Lower than expected protein levels	Cells are not completely lysed.	- Freeze/thaw cells to increase cellular breakage. - Addition of lysozyme (final concentration of 0.2 mg/mL) will aid in protein extraction.
	Sample viscosity is too high.	Addition of Benzonase® (final activity of 50 units/mL) will reduce sample viscosity and aid in recovery of soluble extract.
	Target protein degraded.	- Addition of protease inhibitors may help reduce target protein degradation. - See Reagents and Equipment Required but Not Provided for recommended protease inhibitor cocktails.
	Expression level may be too low.	- Add more inducing agent. - Induce for a longer time period. - Check the construct. - Use another bacterial cell line.
	Protein of interest may be insoluble.	Check pellet to ensure protein of interest has not formed inclusion bodies.

Reagent Compatibility Chart

Reagent	Effect	Comments
Chelating agents (EDTA, EGTA)	Strips metal ions from IMAC resins and chelates essential Mg^{2+}	- EDTA is not compatible with the HIS-Select™ line of products. It will chelate metal ions from the affinity gel. - Addition of EDTA to the original cell lysis mixture will chelate metal ions essential for endonuclease activity. This will result in a thick, viscous solution.
Protease Inhibitors	Prevent protein degradation	Protease inhibitors may be added to the bacterial cell culture extraction, if desired.
2-mercaptoethanol and dithiothreitol	Reducing Agents	- Can be used at low levels for downstream application to HIS-Select™ products. - Should not be used for FLAG® or glutathione resins.

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

B7435bul Rev 03/22 JP,MAM,GCY

